FDA orphan status caught market off guard imo - as far as I am aware it wasn't expected US to follow this closely after EU gave the tick.
As previously stated by the company plenty of interest from big pharma & large biotechnology companies surrounding the trial and progress.
FDA ticking the box yesterday would of increased the "interest" significantly.
Things could move very fast from here on the completion of 4th cohort if it delivers as expected in an open labelled trial.
breakout?, page-30
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $7.419K | 2.372M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 56 | 40557809 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 26688875 | 13 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |